-
MEDUSA Maps Hidden Mechanisms of Drug-Induced Death
2026-09-15
Honeywell and colleagues developed MEDUSA, a simulation-assisted framework that separates drug-induced cell death from changes in proliferation during functional genomic screening. Applied to DNA damage responses, the approach showed that p53 loss redirects cells from apoptosis toward a nonapoptotic, respiration-dependent death program, providing a more precise basis for interpreting genetic drug-sensitivity profiles.
-
AL-8810: Prostaglandin F2α Antagonist Workflow
2026-09-15
Use AL-8810 to isolate FP receptor activity from broader prostaglandin synthesis in endometrial, vascular, ocular, fibroblast, and smooth-muscle models. This workflow connects competitive receptor blockade with ERK1/2, MMP-2, VEGF-A, permeability, and tissue-remodeling readouts.
-
Fluoxetine HCl Workflows for Serotonin Research
2026-09-14
Build concentration-aware receptor, membrane, and behavioral assays with Fluoxetine HCl while controlling solvent, exposure timing, and interpretation. The workflow connects serotonergic signaling to motivation, neurogenesis and synaptic plasticity studies, and developmental SSRI questions without treating one assay as a complete disease model.
-
Thymoquinone and Doxorubicin Cardiotoxicity
2026-09-14
A 2025 mouse study reports that thymoquinone protects against doxorubicin-associated cardiac injury while improving antioxidant defenses and ferroptosis-related markers. Its main contribution is to connect cardioprotection with Nrf2/HO-1 signaling, mitochondrial preservation, and reduced oxidative stress, while also defining important limits for translational interpretation.
-
Malate as a Flux-Control Reagent in Tumor Metabolism
2026-09-13
Malate is a tricarboxylic acid cycle intermediate that can clarify mitochondrial redox, carbon flux, and immune-metabolic phenotypes. This article presents a control-centered framework for using (S)-2-hydroxysuccinic acid to interpret PDHA1-linked tumor metabolism without mistaking correlation for causality.
-
Chenodeoxycholic Acid: FXR Mechanism & Research Use
2026-09-12
Chenodeoxycholic Acid (CDCA) is a hydrophobic primary bile acid and FXR activator used in bile acid metabolism, cholesterol metabolism research, and nuclear receptor signaling studies. Recent preclinical evidence links CDCA-activated FXR to KLF11 induction and suppression of JAK2/STAT3 signaling in a contrast-induced acute kidney injury model.
-
Pentoxifylline Modulates TLR4 Inflammation in Preterm Monocy
2026-09-12
Schüller and colleagues developed an age-stratified whole-blood model to examine how pentoxifylline reshapes LPS-triggered monocyte activation in preterm infants, term infants, and adults. The study connects reduced inflammatory cytokine production and monocyte activation with suppression of TLR4 expression and signaling, while identifying age-dependent differences that are important for neonatal sepsis research.
-
Tamoxifen as a Temporal Tool in Airway Immunology
2026-09-11
Tamoxifen is more than a selective estrogen receptor modulator: in CreER systems, it can help test whether persistent immune-cell clones actively sustain recurrent airway inflammation. This article connects the Nature study of GZMK-expressing CD8+ T cells with rigorous temporal-control and assay-design principles.
-
Cyclo (-RGDfC): From Binding to Assay Design
2026-09-11
Cyclo (-RGDfC) is more than an αvβ3 ligand: it can help separate receptor-mediated biology from nonspecific cytotoxicity. This assay-focused guide integrates peptide chemistry with lessons from canine osteosarcoma viability research.
-
BI 2536 for Reliable PLK1 Assays
2026-09-10
This scenario-driven guide explains how BI 2536 (SKU A3965) can improve interpretation of proliferation, viability, cell-cycle, and apoptosis experiments. It connects PLK1 biology with practical formulation, dosing, controls, and data-analysis decisions supported by product information and published research.
-
Pepstatin A Workflows for Protease Research
2026-09-10
Pepstatin A provides a focused way to interrogate pepsin, renin, HIV protease, and cathepsin D in biochemical and cell-based models. This practical guide connects stock preparation, potency-aware assay design, viral protein processing research, and osteoclast differentiation inhibition with orthogonal validation principles from a recent TET2 protocol.
-
DiscoveryProbe FDA-approved Drug Library: OA
2026-09-09
Use a clinically anchored compound collection to convert an osteoarthritis mechanism into a scalable screening workflow. The approach combines OSCAR-binding assays, chondrocyte phenotyping, high-content confirmation, and drug repositioning screening while preserving a clear path to target validation.
-
SHC-1 Inhibition and CFTR Membrane Trafficking
2026-09-09
A 2026 study shows that MAPK/SHC-1-dependent CFTR internalization is conserved across airway and intestinal epithelial models, while the effects of SHC-1 inhibitors on surface abundance are strongly cell-type dependent. The work identifies a potential trafficking mechanism relevant to CFTR-related disease but also cautions that CFBE cells may not fully represent endogenous epithelial regulation.
-
SU 5402 Workflows for RTK Signaling Research
2026-09-08
SU 5402 enables time-resolved interrogation of VEGFR2, FGFR1, PDGFRβ, and downstream ERK1/2–STAT3 signaling, with especially useful applications in FGFR3-dependent multiple myeloma models. This guide pairs validated oncology workflows with a carefully bounded, exploratory framework for human iPSC-derived sensory-neuron studies.
-
Drug Response Assays: Insights from Schwartz (2022)
2026-09-08
Hannah Schwartz’s 2022 dissertation examines why relative viability and fractional viability should not be treated as interchangeable measures of anticancer drug response. Its central practical contribution is a framework for separating growth inhibition from cell killing across dose and time, improving interpretation of in vitro pharmacology experiments.